CancerDrs

Brain Cancer clinical trials in Colorado

20 actively recruiting brain cancer trials at 17 sites across Colorado.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Colorado:
  • Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
  • Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
  • Kaiser Permanente-Franklin — Denver, Colorado
  • Porter Adventist Hospital — Denver, Colorado
  • SCL Health Saint Joseph Hospital — Denver, Colorado
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Colorado:
  • UCHealth University of Colorado Hospital — Aurora, Colorado
  • UCHealth Memorial Hospital Central — Colorado Springs, Colorado
  • Memorial Hospital North — Colorado Springs, Colorado
  • Poudre Valley Hospital — Fort Collins, Colorado
  • Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
Phase 3 Recruiting Network

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …

Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Colorado:
  • Children's Hospital Colorado — Aurora, Colorado
Phase 3 Recruiting Industry

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …

Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Colorado:
  • University of Colorado Health Cancer Care — Aurora, Colorado
Phase 2 Recruiting Network

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …

Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Colorado:
  • Children's Hospital Colorado — Aurora, Colorado
Phase 1, Phase 2 Recruiting NIH

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in Colorado:
  • UCHealth University of Colorado Hospital — Aurora, Colorado
Phase 1, Phase 2 Recruiting Network

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…

Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Colorado:
  • Children's Hospital Colorado — Aurora, Colorado
Phase 2 Recruiting NIH

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05859334
Sites in Colorado:
  • UCHealth University of Colorado Hospital — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in Colorado:
  • Children's Hospital Colorado - Anschutz Medical Campus — Aurora, Colorado
Phase 2 Recruiting Industry

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receiv…

Sponsor: Biostar Pharma, Inc.
NCT ID: NCT06764940
Sites in Colorado:
  • University Of Colorado Hospital - Anschutz Cancer Pavilion — Aurora, Colorado
Phase 2 Recruiting Industry

Study of Olutasidenib and Temozolomide in HGG

The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to a…

Sponsor: Rigel Pharmaceuticals
NCT ID: NCT06161974
Sites in Colorado:
  • Children's Hospital Colorado — Aurora, Colorado
Phase 2 Recruiting Academic/Other

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell…

Sponsor: Nationwide Children's Hospital
NCT ID: NCT05843253
Sites in Colorado:
  • Children's Hospital Colorado — Aurora, Colorado
Phase 1, Phase 2 Recruiting Academic/Other

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will …

Sponsor: Nationwide Children's Hospital
NCT ID: NCT05278208
Sites in Colorado:
  • Children's Hospital Colorado — Aurora, Colorado
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is …

Sponsor: Pfizer
NCT ID: NCT05355701
Sites in Colorado:
  • Clinical and Translational Research Center (CTRC) — Aurora, Colorado
  • UCHealth Sue Anschutz-Rodgers Eye Center — Aurora, Colorado
  • University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) — Aurora, Colorado
  • University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) — Aurora, Colorado
  • University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) — Aurora, Colorado
Phase 1 Recruiting Network

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or…

Sponsor: Children's Oncology Group
NCT ID: NCT06894979
Sites in Colorado:
  • Children's Hospital Colorado — Aurora, Colorado
EARLY Phase 1 Recruiting Academic/Other

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given. The study wil…

Sponsor: Nationwide Children's Hospital
NCT ID: NCT04655404
Sites in Colorado:
  • Children's Hospital Colorado — Aurora, Colorado
EARLY Phase 1 Recruiting Academic/Other

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with che…

Sponsor: Nationwide Children's Hospital
NCT ID: NCT06333899
Sites in Colorado:
  • Children's Hospital Colorado — Aurora, Colorado
Recruiting Academic/Other

Targeted Pediatric High-Grade Glioma Therapy

The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligi…

Sponsor: Nationwide Children's Hospital
NCT ID: NCT05839379
Sites in Colorado:
  • Children's Hospital Colorado — Aurora, Colorado

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27